Koshinski Asset Management Inc. Makes New $2.65 Million Investment in ResMed Inc. (NYSE:RMD)
Koshinski Asset Management Inc. bought a new position in ResMed Inc. (NYSE:RMD) in the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 10,147 shares of the medical equipment provider’s stock, valued at approximately $2,650,000.
Several other institutional investors and hedge funds also recently modified their holdings of RMD. Regent Peak Wealth Advisors LLC acquired a new stake in shares of ResMed in the 4th quarter worth $30,000. Capital Asset Advisory Services LLC acquired a new stake in shares of ResMed during the 4th quarter worth about $34,000. International Assets Investment Management LLC acquired a new stake in shares of ResMed during the 4th quarter worth about $37,000. JJJ Advisors Inc. increased its position in shares of ResMed by 435.3% during the 4th quarter. JJJ Advisors Inc. now owns 182 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 148 shares during the last quarter. Finally, Bainco International Investors acquired a new stake in shares of ResMed during the 4th quarter worth about $43,000. 68.64% of the stock is owned by institutional investors and hedge funds.
RMD has been the subject of a number of recent analyst reports. Needham & Company LLC raised ResMed from a “hold” rating to a “buy” rating and set a $229.00 price objective for the company in a research report on Monday, March 22nd. Zacks Investment Research downgraded ResMed from a “buy” rating to a “hold” rating and set a $222.00 price objective for the company. in a research report on Wednesday, December 30th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $199.71.
Shares of ResMed stock opened at $197.12 on Thursday. The business has a 50-day moving average of $191.34 and a 200 day moving average of $198.47. ResMed Inc. has a 12 month low of $149.16 and a 12 month high of $224.43. The stock has a market capitalization of $28.68 billion, a price-to-earnings ratio of 42.30, a price-to-earnings-growth ratio of 2.86 and a beta of 0.28. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.61 and a quick ratio of 1.80.
ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, January 28th. The medical equipment provider reported $1.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.19. The business had revenue of $800.00 million during the quarter, compared to analysts’ expectations of $785.07 million. ResMed had a return on equity of 30.64% and a net margin of 22.45%. The business’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.21 EPS. Equities research analysts anticipate that ResMed Inc. will post 5.21 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 18th. Stockholders of record on Thursday, February 11th were paid a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.79%. The ex-dividend date was Wednesday, February 10th. ResMed’s payout ratio is presently 32.77%.
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service.
Recommended Story: What is Depreciation?
Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD).
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.